Subcutaneous administration in horses involves the delivery of medication or other substances into the tissue layer between the skin and muscle. This method is used for various therapeutic and preventative treatments, including vaccinations, analgesics, and fluid administration. The technique requires careful consideration of factors such as needle size, injection site, and volume of the substance to ensure effective absorption and minimize discomfort or complications. Subcutaneous administration is often chosen for its ease of application and potential for sustained release of medication. This page compiles peer-reviewed research studies and scholarly articles that explore the methodology, efficacy, and applications of subcutaneous administration in equine veterinary practice.
Stevenson AJ, Weber MP, Todi F, Young L, Beaumier P, Kacew S.Plasma and urinary concentrations of procaine were examined in Standardbred mares after subcutaneous administration of various doses (80 mg to 1600 mg) of procaine hydrochloride. Regardless of dose, peak plasma procaine values occurred within 1 h, but remained detectable in a dose-dependent manner, with procaine present at 1 h with the 80 mg dose and 6 h at the 1600 mg dose. Similarly, peak urinary procaine concentrations were attained within 1.5 to 3 h, irrespective of dose, while detection time was dose-dependent, being 23 h for 80-200 mg doses but as long as 30-54 h with the 1600 mg dose. W...
Gerhards H, Kietzmann M.Pharmacokinetic parameters for subcutaneous low dose heparin in horses have been determined. Four groups of five and one group of eleven mature, healthy horses of various breeds were given single subcutaneous injections of 60, 80, 100, 125, and 150 units of calcium heparin/kg of body weight (U/kg) in the pectoral region. Jugular blood samples were collected prior to, and at hourly intervals for 12 h after injection. Heparin plasma concentrations were measured using a commercially available amidolytic assay. Peak concentrations 4 h after administration were 0.021 +/- 0.016 (mean +/- SD) units o...
Gerhards H, Eberhardt C.Different doses of heparin were given to equids SC to establish 0.05 to 0.20 U of heparin/ml of plasma. Plasma heparin values and antithrombin III activities were assayed, using chromogenic substrate methods. Activated partial thromboplastin and thrombin times were determined, using conventional coagulation assays. Tests were run every hour (or every 2 hours for antithrombin III) for 12 hours from 5 groups of 5 equids each after single injection of 40, 60, 80, 100, or 125 U of calcium heparin/kg of body weight and from 11 equids after injection of 150 U of calcium heparin/kg. The smaller dose ...
Byars TD, Greene CE, Kemp DT.Warfarin-induced anticoagulation and reversal of the induced anticoagulation by vitamin K1 were evaluated in 4 mature horses. Each horse was given warfarin IV until the prothrombin (PT) time was prolonged by approximately 1.5 times the predosing base-line value. In experiment 1, we evaluated the time required for PT to return to the predosing value (PT reversal time) after warfarin administration was discontinued. Between each experiment, a 1-week rest period was allowed. In experiment 2, two doses of vitamin K1 (100 mg/dose) were administered IM 6 hours apart, and the PT was monitored hourly ...
Douglas RH, Ginther OJ.Several experiments indicated that prostaglandin F2alpha (PGF2alpha) has luteolytic and abortifacient properties in mares. A single subcutaneous injection of 1-25 mg PGF2alpha on Day 6 of dioestrus was as effective as 10 mg PGF2alpha in inducing luteolysis. Oestrus and ovulation appeared to be synchronized when a single injection of 1-25 mg PGF2alpha was given on Days 7, 10 or 13 after ovulation but not on Days 1 or 4 after ovulation or on Day 2 of oestrus. Intramuscular administration was as effective as subcutaneous administration and 1-25 mg PGF2alpha was the minimal effective systemic dose...
Oxender WD, Noden PA, Bolenbaugh DL, Hafs HD.To determine the minimal effective dose of prostagiandin (PGF2alpha; tromethamine salt) given subcutaneously (SC), mares of mixed breeding (400 kg av body weight) were given 2-, 3-, 5-, and 10-mg doses from 7 to 9 days after ovulation. In some but not all mares given doses of 2 and 3 mg of PGF2alpha, luteolysis occurred, but doses of 5 or 10 mg of PGF2alpha were luteolytic in all mares. The 10-mg dose of PGF2alpha did not cause luteolysis in mares 1 day after ovulation, and caused luteolysis in only 2 of 5 mares on day 3 after ovulation. The same dose of PGF2alpha, however, caused luteolysis i...
Souillard A, Audran M, Bressolle F, Jaussaud P, Gareau R.The pharmacokinetics of recombinant human Epo (rHuEpo) were investigated after subcutaneous administration to horses. Four horses received a single 30IU kg-1 dose of rHuEpo. One horse received three repeated doses of 120 IU kg-1 at 48 h intervals. Plasma erythropoietin (Epo) was measured by radioimmunoassay. In both cases pharmacokinetic parameters were evaluated using a one-compartment open model and first-order input and output rates. The mean values (+/-SD) for elimination half-life, CL/F, and Vd/F after a single dose were 12.9 +/- 3.34 h, 11.8 +/- 4.96 L h-1, and 233 +/- 126 L, respectivel...
Oxender WD, Noden PA, Bolenbaugh DL, Hafs HD.To determine the minimal effective dose of prostagiandin (PGF2alpha; tromethamine salt) given subcutaneously (SC), mares of mixed breeding (400 kg av body weight) were given 2-, 3-, 5-, and 10-mg doses from 7 to 9 days after ovulation. In some but not all mares given doses of 2 and 3 mg of PGF2alpha, luteolysis occurred, but doses of 5 or 10 mg of PGF2alpha were luteolytic in all mares. The 10-mg dose of PGF2alpha did not cause luteolysis in mares 1 day after ovulation, and caused luteolysis in only 2 of 5 mares on day 3 after ovulation. The same dose of PGF2alpha, however, caused luteolysis i...
Rostang A, Desjardins I, Espana B, Panzuti P, Berny P, Prouillac C, Pin D.This study aimed to investigate both the pharmacokinetic behavior and tolerance of methotrexate (MTX) in horses to design a specific dosing regimen as a new immunomodulatory drug for long-term treatment. To determine the primary plasma pharmacokinetic variables after single intravenous, subcutaneous or oral administration, six horses were administered 0.3 mg/kg MTX in a crossover design study. After a 10-week washout, MTX was administered subcutaneously to three of the six previously treated horses at a dose of 0.3 mg/kg once per week for 3 months. In both studies, MTX and metabolite concen...
Brandon AM, Williams JM, Davis JL, Martin EG, Capper AM, Crabtree NE.To determine the pharmacokinetics (PK) of metoclopramide administered via intravenous continuous rate infusion (IV CRI) and subcutaneous (SC) bolus and evaluate for gastrointestinal motility and adverse side effects. Methods: Experimental study; randomized, crossover design. Methods: Six healthy adult horses. Methods: Each horse received metoclopramide via IV CRI (0.04 mg/kg/h for 24 h) and SC bolus (0.08 mg/kg once), with ≥1 week washout period between. Plasma was analyzed by UPLC-MS/MS. Compartmental modeling was used to determine PK parameters for each treatment; nonparametric sup...
Honkavaara JM, Karikoski NP, Palvas L, Pypendop BH, Rinne VM, Raekallio MR.The aim of the study was to determine the exposure to subcutaneously administered butorphanol in horses pre-treated with intravenous (IV) detomidine, with or without vatinoxan, a peripherally selective alpha-adrenoceptor antagonist. Five healthy, adult horses received three IV treatments 7 days apart, in a randomized, cross-over design: detomidine 20 μg/kg (DET-B), detomidine 20 μg/kg with vatinoxan 200 μg/kg (DETVAT-B) and saline (S-B), all followed by 0.1 mg/kg of butorphanol administered subcutaneously 30 min later. Venous samples were collected between 10 and 270 min after...
Amiet B, Rainger J, Zedler S, Stewart A, Woldeyohannes S, Goodwin W.To compare horses' aversive behavioural responses to the application of 5% prilocaine/lidocaine eutectic mixture of local anaesthetics (EMLA) cream versus subcutaneous infiltration of 2% lidocaine, followed by jugular vein catheterization. Methods: Blinded, randomized study. Methods: A group of 26 university-owned research horses. Methods: Each horse received both treatments at opposite jugular sites with ≥ 12 hours between procedures. One randomly assigned jugular site received 1 g cm of 5% EMLA cream 60 minutes before catheterization, while the contralateral site received 1.5 mL of 2% lido...
Rangel A, Sellon DC, Sanz MG, Pinnell E, Pietras ZM, Villarino NF.Pharmacokinetics (PK) of intramuscular (IM) and subcutaneous (SC) ketamine in horses has not been described. This study aimed to evaluate the PK and safety of ketamine and its metabolites after a single SC or IM administration. In Phase 1, two horses received 0.5 or 1 mg/kg of ketamine via SC and IM routes. In Phase 2, eight horses received 0.5 mg/kg IM. Plasma or serum concentrations of ketamine and major metabolites were determined by a validated liquid chromatography-mass spectrometry method at baseline and selected intervals post-administration. Subcutaneous administration resulted in ...
